E. Masson

发表

Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet.

D. Stanski, G. Helmlinger, H. Tomkinson, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity.

M. Relling, C. Pui, J. Schuetz, 1997, Molecular pharmacology.

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

M. Relling, C. Pui, W. Evans, 1996, The Journal of clinical investigation.

Lack of Effect of Brivanib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, Administered Intravenously and Orally in Healthy Participants

G. Kollia, E. Masson, P. Clemens, 2012, Journal of clinical pharmacology.

Population exposure–safety analysis of cediranib for Phase I and II studies in patients with cancer

Weifeng Tang, N. Al-Huniti, Jianguo Li, 2018, British journal of clinical pharmacology.

An age‐dependent mathematical model of neurofilament trafficking in healthy conditions

T. Ferguson, I. Nestorov, E. Domenici, 2022, CPT: pharmacometrics & systems pharmacology.

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

K. Bhalla, H. Kantarjian, G. Garcia-Manero, 2006, Clinical Cancer Research.

Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator

Sean Zhang, Daphne D Williams, E. Masson, 2016, British journal of clinical pharmacology.

Metabolism and Disposition of [14C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans

V. Arora, A. Allentoff, J. Gan, 2011, Drug Metabolism and Disposition.

Intravenously and Orally in Healthy Participants Lack of Effect of Brivanib on the Pharmacokinetics of Midazolam , a CYP 3 A 4 Substrate , Administered

G. Kollia, E. Masson, P. Clemens, 2011 .

Metabolism and Disposition of [ 14 C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans □ S

V. Arora, A. Allentoff, J. Gan, 2011 .

Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat).

D. Lebwohl, H. Prince, M. Cooper, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic Optimisation of Cancer Chemotherapy

W. Zamboni, E. Masson, 1997, Clinical pharmacokinetics.

CAFFEINE REDUCES SPONTANEOUS ENEHGY INTAKE IN MEN BUT NOT IN

A. Tremblay, A. Houde, E. Masson, 1988 .

Who Needs Individual Bioequivalence Studies for Narrow Therapeutic Index Drugs? A Case for Warfarin

M. Lebel, A. Yacobi, E. Masson, 2000, Journal of clinical pharmacology.

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.

J. Wolchok, S. Chasalow, S. O’Day, 2013, Cancer immunity.

Clinical Pharmacokinetics and Pharmacodynamics of Cediranib

Weifeng Tang, Jianguo Li, E. Masson, 2017, Clinical Pharmacokinetics.

Development of a physiologically based pharmacokinetic model to predict the effects of flavin‐containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure

Diansong Zhou, S. Neuhoff, N. Al-Huniti, 2017, Biopharmaceutics & drug disposition.

Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer.

U. Vanhoefer, D. Lebwohl, T. Trarbach, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies.

Jeffrey W. Scott, K. Bhalla, D. DeAngelo, 2007 .

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.

J. Cortes, F. Giles, M. Albitar, 2007, Leukemia research.

Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin’s lymphoma

A. Patnaik, H. Burris, M. Mita, 2007 .

Metabolic Chiral Inversion of Brivanib and Its Relevance to Safety and Pharmacology

Yuan-qing Xia, M. Jemal, J. Gan, 2012, Drug Metabolism and Disposition.

Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation.

S. Raimondi, M. Relling, C. Pui, 1999, Blood.

Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer Patients

A. Rottmann, L. Jost, E. Masson, 2006, Drug Metabolism and Disposition.

Pharmacokinetic studies of clindamycin hydrochloride in humans.

C. Metzler, E. Masson, R. Dehaan, 1972, International journal of clinical pharmacology, therapy and toxicology.

Effects of Rifabutin and Rifampicin on the Pharmacokinetics of Ethinylestradiol and Norethindrone

F. Vallée, M. Lebel, P. Narang, 1998, Journal of clinical pharmacology.

Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure

H. Tomkinson, Weifeng Tang, E. Masson, 2017, Clinical pharmacology in drug development.

Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis

L. Schwartz, M. Sznol, K. Fahrbach, 2018, Journal of Cancer Research and Clinical Oncology.

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

D. Berman, S. Parker, E. Masson, 2014, British journal of clinical pharmacology.

Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

J. Weber, Tai-Tsang Chen, E. Masson, 2013, Clinical Cancer Research.

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule

A. Patnaik, N. Vogelzang, M. Mita, 2007 .

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.

Eric Masson, Lucy Lee, Mark A Horsfield, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.

U. Vanhoefer, B. Wiedenmann, T. Trarbach, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers

Diansong Zhou, Weifeng Tang, N. Al-Huniti, 2018, Journal of clinical pharmacology.

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

F. Giles, G. Roboz, M. Schuster, 2006, Leukemia.

Caffeine reduces spontaneous energy intake in men but not in women

J. Després, A. Tremblay, A. Houde, 1988 .

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.

Jürgen Hennig, Eric Masson, Yu-Yun Ho, 2005, European journal of cancer.

Targeting Protein–Protein Interactions: Suppression of Stat3 Dimerization with Rationally Designed Small‐Molecule, Nonpeptidic SH2 Domain Binders

William P. Katt, J. Turkson, S. Sebti, 2008, Chembiochem : a European journal of chemical biology.

Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors

G. Shapiro, P. LoRusso, H. Hurwitz, 2011, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients

Dianna Y. Wu, Jinshan Shen, E. Masson, 2013, Clinical Drug Investigation.

Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer

Karen So, S. Ramalingam, R. Harvey, 2019, Clinical and translational science.

Harnessing Meta‐analysis to Refine an Oncology Patient Population for Physiology‐Based Pharmacokinetic Modeling of Drugs

H. Tomkinson, V. Reddy, K. Vishwanathan, 2018, Clinical pharmacology and therapeutics.

The position of rumenic acid on triacylglycerols alters its bioavailability in rats.

J. Chardigny, E. Masson, J. Sebedio, 2003, The Journal of nutrition.

Association between immune-checkpoint inhibitor induced tumor shrinkage and overall survival in advanced melanoma and NSCLC.

A. Gupta, S. Agrawal, E. Masson, 2014 .

Clinical pharmacokinetics (PK) of BMS-936558, a fully human anti-PD-1 monoclonal antibody.

A. Gupta, S. Agrawal, G. Kollia, 2012 .

Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology

H. Tomkinson, E. Masson, G. Mugundu, 2018, Journal of clinical pharmacology.

Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer

Weifeng Tang, N. Al-Huniti, Jianguo Li, 2017, British journal of clinical pharmacology.

A multiple‐dose safety and bioequivalence study of a narrow therapeutic index drug: A case for carbamazepine

E. Masson, B. Levitt, S. Zlotnick, 1999, Clinical pharmacology and therapeutics.

Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors

T. Mekhail, R. Ganapathi, J. Gan, 2010, Drug Metabolism and Disposition.

Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS‐690514 in Healthy Participants: Assessing the Mechanism of the Interaction With Physiologically‐Based Pharmacokinetic Simulations

V. Roongta, Zheng Yang, E. Masson, 2013, Journal of clinical pharmacology.

Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC)

P. Kantoff, W. Oh, D. Lebwohl, 2004 .

Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC)

B. Wiedenmann, U. Junker, A. Baron, 2005 .

Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia.

C. Pui, J. Schuetz, M. Relling, 1996, Leukemia.

Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC).

P. Kantoff, W. Oh, D. Lebwohl, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.

W. Evans, J. Irvin, D. E. Myers, 1995, Leukemia & lymphoma.

The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases

A. El-Khoueiry, J. Posey, S. Krishnamurthi, 2013, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of vatalanib plus capecitabine in patients with advanced cancer

R. Schilsky, M. Ratain, E. Vokes, 2007, Targeted Oncology.